Cancer Vaccine Safe, Induces T-Cell Responses for KRAS-Mutated Tumors
By Elana Gotkine HealthDay Reporter
FRIDAY, Jan. 12, 2024 -- For patients with immunotherapy recalcitrant KRAS-mutated tumors, the cancer vaccine ELI-002 2P is safe and induces T-cell responses, according to a study published online Jan. 9 in Nature Medicine.
Noting that the cancer vaccine ELI-002 2P enhances lymph node delivery and immune response using Amphiphile (Amph)-modification of G12D and G12R mutant KRAS (mKRAS) peptides (Amph-Peptides-2P) together with CpG oligonucleotide adjuvant (Amph-CpG-7909), Shubham Pant, M.D., M.B.B.S., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues treated 25 patients (20 with pancreatic cancer; five with colorectal cancer) positive for minimal residual mKRAS disease after locoregional treatment in a phase 1 study involving fixed-dose Amph-Peptides-2P and ascending dose Amph-CpG-7909.
The researchers found no dose-limiting toxicities; the recommended phase 2 dose was 10.0 mg Amph-CpG-7909. Overall, 21, 21, and six patients (84, 84, and 24 percent) had direct ex vivo mKRAS-specific T-cell responses, tumor biomarker responses, and biomarker clearance, respectively. Median relapse-free survival was 16.33 months. There was a correlation seen for efficacy with T-cell response; the median tumor biomarker reduction was −76.0 versus −10.2 percent. Median relapse-free survival was not reached compared with 4.01 months (hazard ratio, 0.14).
"Overall, this study provides important proof of concept for the safety and immunogenicity of lymph node-targeting Amphiphile vaccines and yielded promising signals of clinical activity that correlate with the magnitude of ELI-002 2P-induced T-cell response," the authors write.
Several authors disclosed ties to biopharmaceutical companies, including Elicio Therapeutics, which is developing ELI-002 2P and funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted January 2024
Read this next
Recommendations Issued for Palliative RT for Symptomatic Bone Mets
THURSDAY, May 30, 2024 -- In a clinical practice guideline issued by the American Society for Radiation Oncology and published online May 22 in Practical Radiation Oncology...
At-School Vaccination Boosts HPV Vaccination Coverage
THURSDAY, May 30, 2024 -- At-school vaccination may be a useful tool to increase human papillomavirus (HPV) vaccination coverage among adolescents, according to a study published...
Diagnosis of Early-Onset Colorectal Cancer Often Delayed
WEDNESDAY, May 29, 2024 -- Nearly half of individuals diagnosed with early-onset colorectal cancer (EOCRC) present with hematochezia and abdominal pain, and one-quarter present...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.